SCHEMBL2292158

SCHEMBL2292158

COc1ccc(-c2nc3ccc(F)cn3c2Nc2c(C)cc(F)cc2C)c(OCC(N)=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
GAA P10253 3/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
TRPA1 O75762 1/20 0.39
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
ATM Q13315 2/20 0.37
TRIM33 Q9UPN9 4/20 0.37
TRIM24 O15164 1/20 0.37
ALOX5 P09917 1/20 0.35
EPHX2 P34913 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
GLA P06280 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290123 0.94 GAA (0.43) MAPTGAATP53POLBTRPA1
SCHEMBL2290803 0.92 TRPA1 (0.42) MAPTGAATP53POLBTRPA1
SCHEMBL2291110 0.89 TRPA1 (0.42) MAPTGAATP53POLBTRPA1
SCHEMBL2291060 0.88 TRPA1 (0.39) MAPTGAATP53POLBTRPA1
SCHEMBL2287359 0.88 TRPA1 (0.39) MAPTGAATP53POLBTRPA1
SCHEMBL2289236 0.86 TRPA1 (0.45) MAPTGAATP53POLBTRPA1
SCHEMBL2287002 0.86 TRPA1 (0.38) MAPTGAATP53POLBTRPA1
SCHEMBL2292255 0.85 GAA (0.49) MAPTGAATP53POLBTRPA1
SCHEMBL2290086 0.85 GAA (0.43) MAPTGAATP53POLBTRPA1
SCHEMBL2289215 0.84 TRPA1 (0.37) MAPTGAATP53POLBTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885GAA 1202/4885TP53 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.